367 related articles for article (PubMed ID: 36272015)
1. Does the Naked Emperor Parable Apply to Current Perceptions of the Contribution of Renin Angiotensin System Inhibition in Hypertension?
Ferrario CM; Saha A; VonCannon JL; Meredith WJ; Ahmad S
Curr Hypertens Rep; 2022 Dec; 24(12):709-721. PubMed ID: 36272015
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin receptor blockers: evidence for preserving target organs.
Carson P; Giles T; Higginbotham M; Hollenberg N; Kannel W; Siragy HM
Clin Cardiol; 2001 Mar; 24(3):183-90. PubMed ID: 11288962
[TBL] [Abstract][Full Text] [Related]
3. Comparison of type 1 angiotensin II receptor blockers and angiotensin converting enzyme inhibitors in the treatment of hypertension.
Weber MA
J Hypertens Suppl; 1997 Dec; 15(6):S31-6. PubMed ID: 9493125
[TBL] [Abstract][Full Text] [Related]
4. The Pivotal Role of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Hypertension Management and Cardiovascular and Renal Protection: A Critical Appraisal and Comparison of International Guidelines.
Alcocer LA; Bryce A; De Padua Brasil D; Lara J; Cortes JM; Quesada D; Rodriguez P
Am J Cardiovasc Drugs; 2023 Nov; 23(6):663-682. PubMed ID: 37668854
[TBL] [Abstract][Full Text] [Related]
5. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
6. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
[TBL] [Abstract][Full Text] [Related]
7. Should ACE inhibitors and ARBs be used in combination in children?
Stotter BR; Ferguson MA
Pediatr Nephrol; 2019 Sep; 34(9):1521-1532. PubMed ID: 30112656
[TBL] [Abstract][Full Text] [Related]
8. Novel Cardiac Intracrine Mechanisms Based on Ang-(1-12)/Chymase Axis Require a Revision of Therapeutic Approaches in Human Heart Disease.
Reyes S; Varagic J; Ahmad S; VonCannon J; Kon ND; Wang H; Groban L; Cheng CP; Dell'Italia LJ; Ferrario CM
Curr Hypertens Rep; 2017 Feb; 19(2):16. PubMed ID: 28233239
[TBL] [Abstract][Full Text] [Related]
9. Theoretical basis and clinical evidence for differential effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor subtype 1 blockers.
Weir MR; Henrich WL
Curr Opin Nephrol Hypertens; 2000 Jul; 9(4):403-11. PubMed ID: 10926177
[TBL] [Abstract][Full Text] [Related]
10. ACE-Inhibitors in Hypertension: A Historical Perspective and Current Insights.
Cutrell S; Alhomoud IS; Mehta A; Talasaz AH; Van Tassell B; Dixon DL
Curr Hypertens Rep; 2023 Sep; 25(9):243-250. PubMed ID: 37284934
[TBL] [Abstract][Full Text] [Related]
11. Enhancing cardiac protection after myocardial infarction: rationale for newer clinical trials of angiotensin receptor blockers.
Pfeffer MA
Am Heart J; 2000 Jan; 139(1 Pt 2):S23-8. PubMed ID: 10618584
[TBL] [Abstract][Full Text] [Related]
12. [Angiotensin II receptor blockers: current status and future prospects].
Corvol P; Plouin PF
Drugs; 2002; 62 Spec No 1():53-64. PubMed ID: 12036389
[TBL] [Abstract][Full Text] [Related]
13. Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients With CKD: A Bayesian Network Meta-analysis of Randomized Clinical Trials.
Xie X; Liu Y; Perkovic V; Li X; Ninomiya T; Hou W; Zhao N; Liu L; Lv J; Zhang H; Wang H
Am J Kidney Dis; 2016 May; 67(5):728-41. PubMed ID: 26597926
[TBL] [Abstract][Full Text] [Related]
14. [The future of renin inhibition].
Uresin AY; Baran E
Turk Kardiyol Dern Ars; 2009 Oct; 37 Suppl 7():32-8. PubMed ID: 20019475
[TBL] [Abstract][Full Text] [Related]
15. Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
Kjeldsen SE; Julius S
Am Heart J; 2004 Nov; 148(5):747-54. PubMed ID: 15523303
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin-Converting Enzyme Inhibitors in Hypertension: To Use or Not to Use?
Messerli FH; Bangalore S; Bavishi C; Rimoldi SF
J Am Coll Cardiol; 2018 Apr; 71(13):1474-1482. PubMed ID: 29598869
[TBL] [Abstract][Full Text] [Related]
17. Recent changes in the landscape of combination RAS blockade.
Epstein BJ; Smith SM; Choksi R
Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1373-84. PubMed ID: 19900020
[TBL] [Abstract][Full Text] [Related]
18. Differences in the clinical effects of angiotensin-converting enzyme inhibitors and Angiotensin receptor blockers: a critical review of the evidence.
Dézsi CA
Am J Cardiovasc Drugs; 2014 Jun; 14(3):167-73. PubMed ID: 24385234
[TBL] [Abstract][Full Text] [Related]
19. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.
Xue H; Lu Z; Tang WL; Pang LW; Wang GM; Wong GW; Wright JM
Cochrane Database Syst Rev; 2015 Jan; 1():CD008170. PubMed ID: 25577154
[TBL] [Abstract][Full Text] [Related]
20. The impact of ACE inhibition on all-cause and cardiovascular mortality in contemporary hypertension trials: a review.
Ferrari R; Boersma E
Expert Rev Cardiovasc Ther; 2013 Jun; 11(6):705-17. PubMed ID: 23750680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]